Petrelintide, also known as ZP8396, is an experimental amylin analogue developed by Zealand Pharma with Roche, studied for weight management.1,2,3 In ZUPREME 1, a randomized, placebo-controlled Phase 2 trial in 485 adults with obesity, average weight fell by about 8% to 10% at 28 weeks with petrelintide, compared with about 2% with placebo.7 It is not FDA-approved. Phase 3 trials sponsored by Roche were recruiting in late 2026, and none of the sources reviewed here reports an approval in any country.5,6,8
Petrelintide at a glance
What it is
An investigational amylin analogue, also known as ZP8396, from Zealand Pharma and Roche.1,2,3
FDA status
Not FDA-approved. Three Phase 3 trials, including ZUPREME-4 and ZUPREME-5, are registered on ClinicalTrials.gov.5,6,8
Human evidence
One published randomized, placebo-controlled Phase 2 trial in 485 adults, and two small randomized Phase 1 trials. A second Phase 2 trial, in type 2 diabetes, is listed as completed without results in the sources cited here.2,4,7
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
What is petrelintide?
Petrelintide is an experimental amylin analogue also known by its development code, ZP8396.1,2
ClinicalTrials.gov lists Zealand Pharma as the sponsor of its Phase 2 trials and Hoffmann-La Roche as the sponsor of later trials, including a combination study with Zealand Pharma as collaborator.1,3,4
How is petrelintide thought to work?
Petrelintide is designed as a long-acting analogue of amylin, a hormone involved in appetite. The ZUPREME 1 authors describe its mechanism as distinct from that of incretin-based treatments.2,7
The published trials measured its effects on body weight and side effects, but the sources reviewed here do not establish how it produces those effects in people.2,7
What do human studies show?
ZUPREME 1 randomly assigned adults with obesity, or overweight with high blood pressure or abnormal blood fats, to one of five levels of petrelintide or to placebo for 42 weeks, at 32 sites in Poland, Romania and the United States. Of 493 people randomized, 485 received treatment.7
At 28 weeks, average body weight fell by 7.9% to 9.8% across the petrelintide groups and by 1.7% with placebo. Weight kept falling to week 42, by up to 10.7%.7
Nausea was the most common side effect, in 20% of people on petrelintide and 6% on placebo. Vomiting, diarrhoea and constipation were reported at low rates in both groups, and no deaths were reported. Zealand Pharma funded the trial, and several authors are its employees.7
Earlier, two small randomized, placebo-controlled Phase 1 trials described weight reductions and no serious or severe adverse events that emerged during treatment.2
ClinicalTrials.gov also lists a Phase 1 study in people with reduced kidney function, completed as of its January 28, 2026 record. None of these trials can show long-term benefit or rule out uncommon harms, which the Phase 3 program is registered to study.5,6,9
What the evidence base contains
Large randomized human trial ZUPREME 1 (NCT06662539): a multicentre, randomized, double-blind, placebo-controlled Phase 2 trial in 485 adults with obesity, or overweight with high blood pressure or abnormal blood fats, without type 2 diabetes, followed for 42 weeks; the main result was weight change at 28 weeks.7
Controlled human trial Two randomized, blinded, placebo-controlled Phase 1 trials, one following participants for 16 weeks, in normal-weight, overweight or obese adults. The published abstract does not give total enrollment.2
Registered trial without results A Phase 2 trial in overweight or obesity with type 2 diabetes (NCT06926842), sponsored by Zealand Pharma and listed as completed in its September 9, 2026 registry record.4
Registered trial without results ZUPREME-5 (NCT07843472), ZUPREME-4 (NCT07843485) and a third Phase 3 trial in obesity or overweight (NCT07843498), sponsored by Roche and listed as recruiting in their October and November 2026 registry records.5,6,8
No. Petrelintide remains in clinical trials. None of the sources reviewed here reports an approval of petrelintide in any country.5,6,7,8
As of their retained registry records, ZUPREME-5 (October 7, 2026), ZUPREME-4 (November 5, 2026) and a third Phase 3 trial in obesity or overweight (November 5, 2026), all sponsored by Roche, were listed as recruiting.5,6,8
A Phase 2 combination study with enicepatide, sponsored by Roche, was listed as not yet recruiting in its July 7, 2026 record.1
Timeline
Results of two randomized Phase 1 trials of petrelintide are published.2
ClinicalTrials.gov lists the ZUPREME Phase 2 obesity trial as completed.3
ClinicalTrials.gov lists a Phase 2 trial in overweight or obesity with type 2 diabetes as completed.4
Results of the ZUPREME 1 Phase 2 trial are published online in The Lancet Diabetes & Endocrinology.7
The retained ClinicalTrials.gov record of the ZUPREME-5 Phase 3 trial lists it as recruiting.5
The retained ClinicalTrials.gov records of ZUPREME-4 and a third Phase 3 trial list them as recruiting.6,8
What is still unknown?
What the completed Phase 2 trial in people with type 2 diabetes found: its results are not part of the sources cited here.4
Its effects and safety over longer periods and in larger groups, including people with cardiovascular disease or type 2 diabetes, which the Phase 3 trials are registered to study.5,6,8
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Petrelintide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Petrelintide are the records PeptideScanner has selected and published, not every registration or paper about Petrelintide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
In clinical trials; not FDA-approved. A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.↗↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.↗
What the reviewed sources report
The trials reported weight reductions and predominantly mild gastrointestinal adverse events. The early-phase design and limited follow-up do not establish long-term benefit or superior tolerability to another medicine.↗
What remains unresolved?
What do larger, longer controlled trials establish about sustained weight changes and uncommon adverse events?↗
Do head-to-head trials support any comparative benefit or tolerability claim?↗
One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.1
Bottom line from this bounded source set
The trials reported weight reductions and predominantly mild gastrointestinal adverse events. The early-phase design and limited follow-up do not establish long-term benefit or superior tolerability to another medicine.1
Reviewed study record
Two early randomized trials
Design
Single- and multiple-ascending-exposure trials were randomized, blinded and placebo controlled; one part followed participants for 16 weeks.1
Population
Earlier parts enrolled normal-weight or overweight adults; the later multiple-exposure part enrolled adults with overweight or obesity. The abstract does not give total enrollment.1
Outcomes reported
The report described weight reductions and no serious or severe treatment-emergent adverse events. One participant discontinued because of gastrointestinal events.1
Limitations
The trials primarily assess early safety and pharmacology. Their size, follow-up and lack of an active comparator do not establish comparative tolerability or exclude uncommon harms.1
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/dom.70753. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
NCT06662539 records 493 participants in a placebo-controlled phase 2 study of overweight or obesity. The eligibility criteria exclude diabetes and diabetic-range HbA1c, defining a different population from the diabetes program. NCT06662539 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
ZUPREME 2 includes specified background diabetes treatment
NCT06926842 records 221 participants with type 2 diabetes treated with stable metformin, with or without an SGLT2 inhibitor. That background matters when interpreting glycemic or safety findings eventually reported. NCT06926842 ↗
Both primary endpoints concern weight at 28 weeks
Both records specify percentage body-weight change through week 28. This endpoint does not directly measure cardiovascular events, sustained benefit after stopping treatment, or every obesity-related complication. NCT06662539 ↗NCT06926842 ↗
The status updates are not efficacy results
Both retrieved records are marked completed, but neither includes posted summary results. ZUPREME 2 was last updated on September 9, 2026. Any effect estimate needs a separate results source rather than being inferred from completion. NCT06662539 ↗NCT06926842 ↗
What remains to be checked
Match ZUPREME publications or subsequent registry results to each protocol before adding effect estimates.
Review durability, discontinuation, gastrointestinal events and other safety findings in the diabetes and non-diabetes populations separately.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Primary reports of the named peptide administered in people, including pharmacology and secondary human-sample analyses. Reviews, modeling and preclinical reports remain indexed but are outside this human-administration subset.
7 retrieved · 1 included · 6 excluded · 0 awaiting a decision · 1 full-text appraisals
Search terms, record decisions and remaining work
"petrelintide"[Title/Abstract] OR "ZP8396"[Title/Abstract]
Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.
Showing 7 of 7 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 42017294 — include: Two original randomized phase 1 human studies reported in one paper; full-text reading and study-family comparison are separate review steps. Study families: EudraCT-2021-001712-28; EudraCT-2022-001744-26.Structured full-text reading · PMC13243934
This is an editorial structured reading, not a validated risk-of-bias score.
Methods describe an independent unblinded randomization programmer, masked identical vials, and blinded participants and trial staff. Two trials and their cohorts are reported in one paper.
Missing data
Results report 133 randomized and 132 treated. All participants completed the single-exposure trial and the first multiple-exposure part; three active-group participants discontinued in the later part. Weight estimates include a post hoc repeated-measures model.
Outcome selection
Safety and tolerability were primary; body-weight changes were secondary. No formal sample-size calculation was performed. Registry protocols and supplementary tables have not yet been independently reconciled, so selective-reporting risk remains unresolved.
Applicability
One German research center enrolled otherwise healthy adults with normal weight, overweight or obesity. The later part included 48 people, all White and mostly men; observation lasted 16 weeks. No active comparator supports claims of superior tolerability.
Funding and conflicts
Zealand Pharma sponsored the trials and manuscript and participated in design, collection and publication. Several authors were employees or shareholders. This is a potential influence to consider, not evidence that results are false.
Registry comparison
The paper identifies EudraCT 2021-001712-28 and 2022-001744-26. Independent comparison of registered outcomes, amendments and supplements is still pending.
PubMed 42586227 — exclude: Review of the amylin evidence base, not a new administered human study.
PubMed 42452898 — exclude: Review of the amylin evidence base, not a new administered human study.
PubMed 41747885 — exclude: Review of the amylin evidence base, not a new administered human study.
PubMed 41344603 — exclude: Review of the amylin evidence base, not a new administered human study.
PubMed 41217931 — exclude: Compound-development and preclinical potency report; the abstract describes clinical development rather than reporting a human administration trial.
PubMed 40608546 — exclude: Preclinical development of a different analogue, BGM1812, not a human petrelintide administration report.
ClinicalTrials.gov search
ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.
9 retrieved · 8 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals
Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
Other registries and unregistered studies are outside this search.
Petrelintide has one ambiguous registry identity; the second trial publication linkage remains incompletely reconciled.
Showing 9 of 9 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT07338214 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07338214.
ClinicalTrials.gov NCT05096598 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05096598.
ClinicalTrials.gov NCT06926842 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06926842.
ClinicalTrials.gov NCT06662539 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06662539.
ClinicalTrials.gov NCT07076030 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07076030.
ClinicalTrials.gov NCT05613387 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05613387.
ClinicalTrials.gov NCT07589686 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07589686.
ClinicalTrials.gov NCT07682818 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07682818.
ClinicalTrials.gov NCT06951854 — unresolved: Autism NV01-A02 record contains a conflicting placebo name mentioning ZP8396; identity is unresolved.
FDA search
Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
products.active_ingredients.name:"PETRELINTIDE" OR products.active_ingredients.name:"ZP8396"
This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Petrelintide?
In clinical trials; not FDA-approved. A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.↗↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationRecruiting 4Completed 3Not yet recruiting 1
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
A status value is unavailable here for 2 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
1 of 2 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 1
Bibliography fields unavailable here for 1 selected record; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
12
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 12 dated records
We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.
ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
We added a plain-language reader guide with cited answers, Phase 1 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 2 and Phase 3 trials.
Selected records span January 28, 2026 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07843485 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07843498 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PubMed lists PMID 42810353 in The lancet. Diabetes & endocrinology as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug petrelintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT06926842 at 2026-09-09T19:17:17.080Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07589686 at 2026-08-13T05:52:27.014Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42017294 at 2026-08-10T18:13:48.775Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-04-22. PeptideScanner associated this retained record with the identity slug petrelintide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT07682818 at 2026-08-10T18:10:03.938Z. Its registry update date was 2026-07-06, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07076030 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was petrelintide.↗